Fennec Pharmaceuticals Announces Investigator-Sponsored Trial
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a notable specialty pharmaceutical company, is gearing up to launch an investigator-sponsored study orchestrated by City of Hope. This trial will focus on the evaluation of PEDMARK (sodium thiosulfate injection), specifically assessing its potential in preventing cisplatin-induced ototoxicity (CIO) among adult men diagnosed with stage II-III metastatic testicular germ cell tumors.
Study Objectives and Background
Cisplatin has drastically improved survival rates for patients with testicular germ cell tumors, converting what was once a near-certain fatality into a manageable condition. However, the adverse effects associated with its usage, notably permanent hearing loss, are significant. Research indicates that nearly 80% of patients who survive the treatment suffer from hearing impairment that substantially harms their quality of life beyond treatment.
“The City of Hope's initiative aims to explore how we can incorporate hearing protection into comprehensive cancer care,” explains Alexander Chehrazi-Raffle, M.D., who serves as the principal investigator for this groundbreaking study. The rising acknowledgment of hearing loss among this demographic emphasizes an urgent need for preventive strategies.
Trial Details
Located in Duarte, California, City of Hope will lead this phase I study, titled "Testing the Addition of PEDMARK to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors." The trial aims to examine whether the addition of PEDMARK to traditional cisplatin chemotherapy effectively mitigates the risk of ototoxicity.
Importance of Addressing Ototoxicity
Ototoxicity, often a consequence of cisplatin and other platinum-based chemotherapy treatments, poses a significant risk. These therapies, while successful in extending life, frequently result in irreversible hearing loss. Studies reveal that between 60-90% of patients treated with cisplatin might experience such auditory challenges, depending on various factors including the intensity and duration of the treatment.
The demand for solutions is pressing, as many patients find themselves requiring lifelong hearing aids, adding a financial burden alongside their health challenges. Hearing loss can affect numerous aspects of life, such as social interaction, educational opportunities, and employment prospects. Effective audiologic monitoring is currently recommended, yet it remains underutilized in certain patient populations.
Introduction and Use of PEDMARK
PEDMARK is the first FDA-approved therapy designated to lessen the risk of ototoxicity linked to cisplatin in pediatric patients. It has been formulated uniquely for ease of use with ready-to-administer vials for intravenous application. Furthermore, it’s endorsed by the National Comprehensive Cancer Network for adolescent and young adult populations.
Annually, approximately 500,000 patients in the U.S. are diagnosed with cancers treatable by platinum-based chemotherapy, where hearing conservation is paramount. Before PEDMARK's approval, no preventative treatments existed for therapy-induced hearing loss. The FDA-approved treatment brought a new horizon for protecting patients against hearing damage while undergoing essential cancer therapies.
Fennec Pharmaceuticals’ Commitment
Fennec Pharmaceuticals is diligently working to broaden the accessibility of PEDMARK, which received FDA approval in September 2022 and was followed by European Commission and U.K. endorsements. Recently, the company entered into an exclusive partnership with Norgine Pharmaceuticals Ltd., facilitating the commercialization of PEDMARK within European markets.
Through these collective efforts, Fennec’s mission to mitigate the impact of chemotherapy on patients’ auditory health continues to gain momentum, aligning survival rates with quality of life improvements. As cancer incidence rises, particularly among younger demographics, it becomes crucial to focus on survivorship and the long-term wellbeing of these patients.
Frequently Asked Questions
What is the purpose of the Fennec Pharmaceuticals trial?
The trial aims to evaluate the effectiveness of PEDMARK in preventing hearing loss among adult male cancer patients undergoing cisplatin treatment.
How does cisplatin affect hearing?
Cisplatin can cause severe hearing loss as a side effect, with research showing that a significant percentage of patients experience ototoxicity following treatment.
What is PEDMARK and its role in the study?
PEDMARK is an FDA-approved treatment designed to reduce the risk of ototoxicity in pediatric cancer patients, and it is now being evaluated for use in adult male patients.
Why is addressing hearing loss in cancer treatment important?
Preventing hearing loss enhances the overall quality of life for survivors, allowing them to maintain better communication, social interaction, and independence post-treatment.
What future plans does Fennec Pharmaceuticals have?
Fennec aims to strengthen its clinical foundation through further research and collaborations, expanding the evidence base for PEDMARK's efficacy in various patient demographics.
